Capricor Therapeutics to Present at Upcoming Conferences

SAN DIEGO, May 08, 2024 – Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company known for developing innovative cell and exosome-based therapies for rare diseases, has announced its participation in several upcoming scientific and medical conferences. Here is a detailed schedule of their planned engagements:

Firstly, Capricor will present at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting in Baltimore, MD, from May 7 to 11, 2024. The company will deliver an oral presentation on "Exosome-mediated intracellular delivery of arginase-1," exploring its potential application for treating Arginase-1 Deficiency.

Next, Capricor will join the Parent Project Muscular Dystrophy (PPMD) Cardiac Workshop III, also in Baltimore, MD, on May 9 and 10, 2024. This session will feature a panel discussion focusing on industry perspectives regarding cardiac monitoring in Duchenne Muscular Dystrophy (DMD) clinical trials.

Following that, the company is scheduled to attend the International Society of Extracellular Vesicles (ISEV) 2024 Meeting in Melbourne, Australia, from May 9 to 12, 2024. Here, Capricor will present an abstract titled "Targeted cargo delivery to mouse lower limb by exosomes carrying a muscle targeting moiety with intravenous injection."

Later in the month, Capricor will participate in the CureDuchenne 2024 FUTURES National Conference held in Orlando, FL, from May 23 to 26, 2024. The presentation will focus on "CAP-1002: an allogeneic cell therapy demonstrates disease modification in later-stage DMD patients," discussing the 24-month safety and efficacy results from the HOPE-2 open label extension study.

Finally, Capricor will present at the International Society for Cell & Gene Therapy (ISCT) 2024 Meeting in Vancouver, Canada, from May 29 to June 1, 2024. An oral presentation on "Targeted delivery of ASO using exosomes leads to mouse dystrophin exon skipping" will be delivered.

All posters and abstracts from these events will be available in the publications section of the Capricor website after the meetings conclude.

About Capricor Therapeutics

Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a biotechnology firm focused on advancing cell and exosome-based therapies to revolutionize treatment for rare diseases. Their lead product candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy. It has shown promising results in preclinical and clinical studies, specifically in its immunomodulatory, antifibrotic, and regenerative effects tailored for dystrophinopathies and heart disease. CAP-1002 is currently in Phase 3 clinical development for treating Duchenne Muscular Dystrophy (DMD).

Capricor is also pioneering their exosome technology using the StealthX™ platform in preclinical research. This technology aims at targeted delivery of oligonucleotides, proteins, and small molecule therapeutics, potentially treating and preventing a variety of diseases.

Capricor is dedicated to pushing the boundaries of medical possibility, striving to develop transformative treatments for patients in need. Their ongoing efforts in research and development underscore their commitment to innovation and patient care.

Capricor has formed a partnership with Nippon Shinyaku Co., Ltd. (U.S. subsidiary: NS Pharma, Inc.) for the exclusive commercialization and distribution of CAP-1002 for DMD in the United States and Japan, pending regulatory approval. Currently, CAP-1002 is classified as an Investigational New Drug and is not approved for any indications. Additionally, none of Capricor’s exosome-based candidates have received approval for clinical investigation.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!